Paracetamol on Postoperative Nausea and Vomiting

The Effect of Paracetamol on Postoperative Nausea and Vomiting Following Maxillofacial Surgery: a Prospective, Randomised, Double-blind Study

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03588338

Enrollment

Registered

2018-07-17

Start date

2018-07-20

Completion date

2018-08-21

Last updated

2020-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting

Keywords

PONV, Paracetamol

Brief summary

The drugs with both high potency and low side effects are preferred in the prevention of postoperative nausea and vomiting (PONV) which is a common problem. This prospective randomized study aimed to compare the efficacy of paracetamol on PONV in adults undergoing maxillofacial surgery.

Detailed description

One hundred-twenty patients are randomly divided into two groups; the paracetamol group who received the IV infusion of paracetamol (1.5 ml/kg); and the metoclopramide group who received the IV infusion of saline (1.5 mg/kg). The presence of vomiting and the actions indicative of nausea, such as repeated gagging or spitting, within 24h following general anesthesia are defined as PONV. All PONV episodes and postoperative pain scores are recorded during 24h postoperatively. The postoperative 0-4h and 4-24h are defined as early and late postoperative period, respectively. Intravenous 4 mg ondansetron as rescue antiemetic drug is administered in case of two or more vomiting episodes.

Interventions

DRUGPerfalgan

For postoperative pain

DRUGControl

For postoperative nausea and vomiting

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* ASA (the classification of the American Society of Anesthesiologists) physical status I-II * Patients who scheduled for elective maxillofacial surgery under general anesthesia

Exclusion criteria

* Patients with a history of allergy to any of the study medications (opioid, general anesthetic agents or paracetamol) * History of opioid use, hepatic or renal disease, coronary, psychotic and neurologic diseases * Use of antiemetic, antihistaminic, analgesic or corticosteroid 24 hours (h) prior to surgery

Design outcomes

Primary

Measure	Time frame	Description
Preventing of postoperative nausea and vomiting	First 24 hours postoperatively	Preventing of postoperative nausea and vomiting in postoperative care unit

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026